A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Thomas Jefferson University
Cellectar Biosciences, Inc.
Massachusetts General Hospital
Wake Forest University Health Sciences
Celgene
University of Miami
Pfizer
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Massachusetts General Hospital
Assistance Publique - Hôpitaux de Paris
Massachusetts General Hospital
Shandong New Time Pharmaceutical Co., LTD
Icahn School of Medicine at Mount Sinai
University of Leeds
Institut Curie
Ontario Clinical Oncology Group (OCOG)
UNC Lineberger Comprehensive Cancer Center
Massachusetts General Hospital
GlaxoSmithKline
Qilu Pharmaceutical Co., Ltd.
Amgen
AbbVie
City of Hope Medical Center
Celgene
Rapa Therapeutics LLC
Hadassah Medical Organization
Gruppo Italiano Malattie EMatologiche dell'Adulto
Intergroupe Francophone du Myelome
SWOG Cancer Research Network
University of Leeds
Peter MacCallum Cancer Centre, Australia
The First Affiliated Hospital of Xiamen University
pharmaand GmbH
Hellenic Society of Hematology
University of Leeds
European Myeloma Network B.V.
University of Heidelberg Medical Center
Oncotherapeutics
Canadian Cancer Trials Group
Antengene Corporation
Celgene
Hrain Biotechnology Co., Ltd.
Hackensack Meridian Health
Tulane University
Canadian Myeloma Research Group
AbbVie
University of Arkansas
University of Arkansas
Merck Sharp & Dohme LLC
Fred Hutchinson Cancer Center